Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz

Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial is a phase 2, randomised interventional study registered as NCT07594925 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 130 participants, started 2026-05-01 and due to reach its primary completion in 2029-06-01. Interventions recorded: Sintilimab; Chemotherapy Drugs; radiotherapy. Conditions listed: Rectal Cancer. Primary outcome: DFS. Colorectal eligibility wording from the registry: "The lower boundary of the lesion is ≤ 10 cm from the anal verge, confirmed by colonoscopy or digital rectal examination;". Sites: China. No results are recorded here; the registry entry is the source.